{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:23:59Z","timestamp":1793643839876,"version":"4.5.1"},"reference-count":292,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503442"],"award-info":[{"award-number":["82503442"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303610"],"award-info":[{"award-number":["82303610"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372943, 82573181"],"award-info":[{"award-number":["82372943, 82573181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2025NSCQ-GPX1144"],"award-info":[{"award-number":["CSTB2025NSCQ-GPX1144"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Foundation of Hunan Aerospace Hospital","award":["2025YJ01"],"award-info":[{"award-number":["2025YJ01"]}]},{"name":"Science Foundation of the AMHT Group","award":["2025YK06"],"award-info":[{"award-number":["2025YK06"]}]},{"name":"Chongqing Medical Youth Top Talent Program","award":["YXQN202558"],"award-info":[{"award-number":["YXQN202558"]}]},{"name":"Chongqing Youth Innovation Talent Project","award":["CSTB2025YITP-QCRCX0096"],"award-info":[{"award-number":["CSTB2025YITP-QCRCX0096"]}]},{"name":"The science and technology innovation Program of Hunan Province","award":["2023RC3074"],"award-info":[{"award-number":["2023RC3074"]}]},{"name":"Key R&D Program of Jiangxi Province","award":["20243BBI91007"],"award-info":[{"award-number":["20243BBI91007"]}]},{"name":"Jiangxi Provincial Health Technology Project","award":["202510008"],"award-info":[{"award-number":["202510008"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Gilead2024-PT-0070"],"award-info":[{"award-number":["Y-Gilead2024-PT-0070"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC220048"],"award-info":[{"award-number":["20252BAC220048"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02594-w","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:34:47Z","timestamp":1771295687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs"],"prefix":"10.1186","volume":"25","author":[{"given":"Chengli","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoqu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2594_CR1","doi-asserted-by":"crossref","unstructured":"Blanchard Z, Brown EA, Ghazaryan A, Welm AL. PDX models for functional precision oncology and discovery science. Nat Rev Cancer. 2024;25(3):153166.","DOI":"10.1038\/s41568-024-00779-3"},{"key":"2594_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","volume":"19","author":"ER Zanella","year":"2022","unstructured":"Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol. 2022;19:719\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"2594_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8:160.","journal-title":"Signal Transduct Target Ther"},{"key":"2594_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101520","volume":"12","author":"M Liu","year":"2025","unstructured":"Liu M, Yang X. Patient-derived xenograft models: current status, challenges, and innovations in cancer research. Genes Dis. 2025;12:101520.","journal-title":"Genes Dis"},{"key":"2594_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29794-4","volume":"13","author":"R Caeser","year":"2022","unstructured":"Caeser R, Egger JV, Chavan S, Socci ND, Jones CB, Kombak FE, et al. Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nat Commun. 2022;13:2144.","journal-title":"Nat Commun"},{"key":"2594_CR6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.trecan.2023.05.001","volume":"9","author":"MA Goyette","year":"2023","unstructured":"Goyette MA, Lipsyc-Sharf M, Polyak K. Clinical and translational relevance of intratumor heterogeneity. Trends Cancer. 2023;9:726\u201337.","journal-title":"Trends Cancer"},{"key":"2594_CR7","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019101654","volume":"38","author":"M Bleijs","year":"2019","unstructured":"Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid model systems in cancer research. EMBO J. 2019;38:e101654.","journal-title":"EMBO J"},{"key":"2594_CR8","first-page":"715","volume":"20","author":"B Qin","year":"2017","unstructured":"Qin B, Jiao X, Yuan L, Liu K, Zang Y. Advances in patient derived tumor xenograft (PDTX) model from lung cancer. Zhongguo Fei Ai Za Zhi. 2017;20:715\u20139.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"2594_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.745","volume":"5","author":"V Janitri","year":"2024","unstructured":"Janitri V, Aruljothi KN, Ravi MV, Singh SK, Prasher P, Gupta G, et al. The roles of patient-derived xenograft models and artificial intelligence toward precision medicine. MedComm. 2024;5:e745.","journal-title":"MedComm"},{"key":"2594_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00268-6","volume":"6","author":"A Hoge","year":"2022","unstructured":"Hoge A, Getz M, Zimmer A, Ko M, Raz L, Beroukhim R, et al. DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis Oncol. 2022;6:30.","journal-title":"NPJ Precis Oncol"},{"key":"2594_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/gm544","volume":"6","author":"R Martinez-Garcia","year":"2014","unstructured":"Martinez-Garcia R, Juan D, Rausell A, Munoz M, Banos N, Menendez C, et al. Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med. 2014;6:27.","journal-title":"Genome Med"},{"key":"2594_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20:192\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"key":"2594_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41568-023-00568-4","volume":"23","author":"JD Hebert","year":"2023","unstructured":"Hebert JD, Neal JW, Winslow MM. Dissecting metastasis using preclinical models and methods. Nat Rev Cancer. 2023;23:391\u2013407.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR14","unstructured":"US Food and Drug Administration. New approach methods (NAMs). 2024.\u00a0https:\/\/www.fda.gov\/food\/toxicology-research\/new-approach-methods-nams."},{"key":"2594_CR15","unstructured":"National Institutes of Health (NIH). NIH to prioritize human-based research technologies. 2025.\u00a0https:\/\/www.nih.gov\/news-events\/news-releases\/nih-prioritize-human-based-research-technologies."},{"key":"2594_CR16","unstructured":"Buntz, B. NIH announces end to funding for animal-only studies. 2025.\u00a0https:\/\/www.drugdiscoverytrends.com\/nih-announces-end-to-funding-for-animal-only-studies\/."},{"key":"2594_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.stem.2025.08.014","volume":"32","author":"CN Svendsen","year":"2025","unstructured":"Svendsen CN. Adopting novel alternative methods (NAMs) for biomedical research-what is the right approach? Cell Stem Cell. 2025;32:1489\u201390.","journal-title":"Cell Stem Cell"},{"key":"2594_CR18","unstructured":"Fiona Sewell, James McBlane, Karen Sturgeon, Helen-Marie Dunmore. Incorporating new approach methodologies in the development of new medicines. 2025.\u00a0https:\/\/www.washington.edu\/aco3rs\/2025\/09\/16\/report-incorporating-new-approach-methodologies-in-the-development-of-new-medicines-nc3rs\/."},{"key":"2594_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1600-0463.2007.apm_689a.x","volume":"115","author":"J Rygaard","year":"2007","unstructured":"Rygaard J, Povsen CO. Heterotransplantation of a human malignant tumour to \u201cnude\u201d mice. 1969. APMIS. 2007;115:604\u20136, 607\u20138.","journal-title":"APMIS"},{"key":"2594_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3109\/08830189609061753","volume":"13","author":"S Nonoyama","year":"1996","unstructured":"Nonoyama S, Ochs HD. Immune deficiency in SCID mice. Int Rev Immunol. 1996;13:289\u2013300.","journal-title":"Int Rev Immunol"},{"key":"2594_CR21","first-page":"259","volume":"152","author":"RA Phillips","year":"1989","unstructured":"Phillips RA, Jewett MA, Gallie BL. Growth of human tumors in immune-deficient SCID mice and nude mice. Curr Top Microbiol Immunol. 1989;152:259\u201363.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2594_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","volume":"154","author":"LD Shultz","year":"1995","unstructured":"Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice. J Immunol. 1995;154:180\u201391.","journal-title":"J Immunol"},{"key":"2594_CR23","doi-asserted-by":"crossref","unstructured":"Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells. 2019;13;8(8):889.","DOI":"10.3390\/cells8080889"},{"key":"2594_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12864-022-08367-1","volume":"23","author":"Z Dudova","year":"2022","unstructured":"Dudova Z, Conte N, Mason J, Stuchlik D, Pesa R, Halmagyi C, et al. The EurOPDX data portal: an open platform for patient-derived cancer xenograft data sharing and visualization. BMC Genomics. 2022;23:156.","journal-title":"BMC Genomics"},{"key":"2594_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature.2016.19364","volume":"530","author":"H Ledford","year":"2016","unstructured":"Ledford H. US cancer institute to overhaul tumour cell lines. Nature. 2016;530:391.","journal-title":"Nature"},{"key":"2594_CR26","unstructured":"Koc, S., Lloyd, M.W., Grover, J.W., Xiao, N., Seepo, S., Subramanian, S.L., Ray, M., Frech, C., Digiovanna, J., and Webster, P., et al. PDXNet portal: patient-derived xenograft model, data, workflow and tool discovery. NAR Cancer. 2022;4:zcac014."},{"key":"2594_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-0716-3858-3_2","volume":"2806","author":"S Aslani","year":"2024","unstructured":"Aslani S, Saad MI. Patient-derived xenograft models in cancer research: methodology, applications, and future prospects. Methods Mol Biol. 2024;2806:9\u201318.","journal-title":"Methods Mol Biol"},{"key":"2594_CR28","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/s41596-024-00998-w","volume":"19","author":"SI De Vleeschauwer","year":"2024","unstructured":"De Vleeschauwer SI, van de Ven M, Oudin A, Debusschere K, Connor K, Byrne AT, et al. Observe: guidelines for the refinement of rodent cancer models. Nat Protoc. 2024;19:2571\u201396.","journal-title":"Nat Protoc"},{"key":"2594_CR29","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/s41596-020-0335-3","volume":"15","author":"V Padmanaban","year":"2020","unstructured":"Padmanaban V, Grasset EM, Neumann NM, Fraser AK, Henriet E, Matsui W, et al. Organotypic culture assays for murine and human primary and metastatic-site tumors. Nat Protoc. 2020;15:2413\u201342.","journal-title":"Nat Protoc"},{"key":"2594_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2017.307","volume":"50","author":"J Jung","year":"2018","unstructured":"Jung J, Seol HS, Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat. 2018;50:1\u201310.","journal-title":"Cancer Res Treat"},{"key":"2594_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985154","volume":"12","author":"X Yu","year":"2022","unstructured":"Yu X, Chen Y, Lu J, He K, Chen Y, Ding Y, et al. Patient-derived xenograft models for gastrointestinal tumors: a single-center retrospective study. Front Oncol. 2022;12:985154.","journal-title":"Front Oncol"},{"key":"2594_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.21147\/j.issn.1000-9604.2021.04.04","volume":"33","author":"J Zhuo","year":"2021","unstructured":"Zhuo J, Lu D, Wang J, Lian Z, Zhang J, Li H, et al. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chin J Cancer Res. 2021;33:470\u20139.","journal-title":"Chin J Cancer Res"},{"key":"2594_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01794-w","volume":"26","author":"J Lee","year":"2024","unstructured":"Lee J, Lee G, Park HS, Jeong BK, Gong G, Jeong JH, et al. Factors associated with engraftment success of patient-derived xenografts of breast cancer. Breast Cancer Res. 2024;26:49.","journal-title":"Breast Cancer Res"},{"key":"2594_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04444-5","volume":"21","author":"L Liu","year":"2023","unstructured":"Liu L, Wu M, Huang A, Gao C, Yang Y, Liu H, et al. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient\u2019s response to conventional and novel therapies. J Transl Med. 2023;21:611.","journal-title":"J Transl Med"},{"key":"2594_CR35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/os.13211","volume":"14","author":"M Sun","year":"2022","unstructured":"Sun M, Wang Z, Sun W, Chen M, Ma X, Shen J, et al. Correlation between patient-derived xenograft modeling and prognosis in osteosarcoma. Orthop Surg. 2022;14:1161\u20136.","journal-title":"Orthop Surg"},{"key":"2594_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101631","volume":"5","author":"T Qin","year":"2024","unstructured":"Qin T, Hu Z, Zhang L, Lu F, Xiao R, Liu Y, et al. Genomic profiling of a multi-lineage and multi-passage patient-derived xenograft biobank reflects heterogeneity of ovarian cancer. Cell Rep Med. 2024;5:101631.","journal-title":"Cell Rep Med"},{"key":"2594_CR37","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1535-7163.MCT-16-0721","volume":"16","author":"A Katsiampoura","year":"2017","unstructured":"Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, et al. Modeling of patient-derived xenografts in colorectal cancer. Mol Cancer Ther. 2017;16:1435\u201342.","journal-title":"Mol Cancer Ther"},{"key":"2594_CR38","doi-asserted-by":"publisher","first-page":"S441","DOI":"10.33549\/physiolres.933526","volume":"65","author":"I Szadvari","year":"2016","unstructured":"Szadvari I, Krizanova O, Babula P. Athymic nude mice as an experimental model for cancer treatment. Physiol Res. 2016;65:S441\u201353.","journal-title":"Physiol Res"},{"key":"2594_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3892\/ijo.2015.2997","volume":"47","author":"T Chijiwa","year":"2015","unstructured":"Chijiwa T, Kawai K, Noguchi A, Sato H, Hayashi A, Cho H, et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol. 2015;47:61\u201370.","journal-title":"Int J Oncol"},{"key":"2594_CR40","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1101\/pdb.top073585","volume":"2014","author":"LD Shultz","year":"2014","unstructured":"Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014;2014:694\u2013708.","journal-title":"Cold Spring Harb Protoc"},{"key":"2594_CR41","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12185-008-0215-z","volume":"88","author":"S Okada","year":"2008","unstructured":"Okada S, Harada H, Ito T, Saito T, Suzu S. Early development of human hematopoietic and acquired immune systems in new born NOD\/scid\/jak3null mice intrahepatic engrafted with cord blood-derived CD34 + cells. Int J Hematol. 2008;88:476\u201382.","journal-title":"Int J Hematol"},{"key":"2594_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.1093933","volume":"304","author":"E Traggiai","year":"2004","unstructured":"Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (New York, NY). 2004;304:104\u20137.","journal-title":"Science (New York, NY)"},{"key":"2594_CR43","volume":"2011","author":"A Ono","year":"2011","unstructured":"Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H, et al. Comparative study of human hematopoietic cell engraftment into BALB\/c and c57BL\/6 strain of rag-2\/jak3 double-deficient mice. J Biomed Biotechnol. 2011;2011:539748.","journal-title":"J Biomed Biotechnol"},{"key":"2594_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-021-00301-6","volume":"21","author":"A Honkala","year":"2022","unstructured":"Honkala A, Malhotra SV, Kummar S, Junttila MR. Harnessing the predictive power of preclinical models for oncology drug development. Nat Rev Drug Discov. 2022;21:99\u2013114.","journal-title":"Nat Rev Drug Discov"},{"key":"2594_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41388-023-02929-7","volume":"43","author":"MG Oser","year":"2024","unstructured":"Oser MG, Macpherson D, Oliver TG, Sage J, Park KS. Genetically-engineered mouse models of small cell lung cancer: the next generation. Oncogene. 2024;43:457\u201369.","journal-title":"Oncogene"},{"key":"2594_CR46","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","volume":"184","author":"S Kaczanowska","year":"2021","unstructured":"Kaczanowska S, Beury DW, Gopalan V, Tycko AK, Qin H, Clements ME, et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell. 2021;184:2033\u201352.","journal-title":"Cell"},{"key":"2594_CR47","doi-asserted-by":"crossref","unstructured":"Uezumi A, Ikemoto-Uezumi M, Zhou H, Kurosawa T, Yoshimoto Y, Nakatani M, Hitachi K, Yamaguchi H, Wakatsuki S, Araki T, et al. Mesenchymal bmp3b expression maintains skeletal muscle integrity and decreases in age-related sarcopenia. J Clin Invest. 2021;131(1):e139617.","DOI":"10.1172\/JCI139617"},{"key":"2594_CR48","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jcsm.12709","volume":"12","author":"WQ Xie","year":"2021","unstructured":"Xie WQ, He M, Yu DJ, Wu YX, Wang XH, Lv S, et al. Mouse models of sarcopenia: classification and evaluation. J Cachexia Sarcopenia Muscle. 2021;12:538\u201354.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2594_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20:192\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"key":"2594_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010112","volume":"15","author":"K Kaur","year":"2022","unstructured":"Kaur K, Jewett A. Differences in tumor growth and differentiation in NSG and humanized-BLT mice; analysis of human vs. humanized-BLT-derived NK expansion and functions. Cancers. 2022;15:112.","journal-title":"Cancers"},{"key":"2594_CR51","doi-asserted-by":"crossref","unstructured":"Sarnella A, Ferrara Y, Terlizzi C, Albanese S, Monti S, Licenziato L, Mancini M. The chicken embryo: an old but promising model for in vivo preclinical research. Biomedicines. 2024;12(12):2835.","DOI":"10.3390\/biomedicines12122835"},{"key":"2594_CR52","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/neuonc\/noad047","volume":"25","author":"M Charbonneau","year":"2023","unstructured":"Charbonneau M, Harper K, Brochu-Gaudreau K, Perreault A, Roy LO, Lucien F, et al. The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity\/resistance in malignant glial tumors. Neuro-Oncol. 2023;25:1605\u201316.","journal-title":"Neuro-Oncol"},{"key":"2594_CR53","doi-asserted-by":"crossref","unstructured":"Chen L, Wang S, Feng Y, Zhang J, Du Y, Zhang J, Ongeval CV, Ni Y, Li Y. Utilisation of chick embryo chorioallantoic membrane as a model platform for imaging-navigated biomedical research. Cells. 2021;10(2):463.","DOI":"10.3390\/cells10020463"},{"key":"2594_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14740\/wjon1763","volume":"15","author":"K Joshi","year":"2024","unstructured":"Joshi K, Katam T, Hegde A, Cheng J, Prather RS, Whitworth K, et al. Pigs: large animal preclinical cancer models. World J Oncol. 2024;15:149\u201368.","journal-title":"World J Oncol"},{"key":"2594_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ame2.12223","volume":"5","author":"N Hou","year":"2022","unstructured":"Hou N, Du X, Wu S. Advances in pig models of human diseases. Anim Model Exp Med. 2022;5:141\u201352.","journal-title":"Anim Model Exp Med"},{"key":"2594_CR56","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa2120238","volume":"386","author":"RA Montgomery","year":"2022","unstructured":"Montgomery RA, Stern JM, Lonze BE, Tatapudi VS, Mangiola M, Wu M, et al. Results of two cases of pig-to-human kidney xenotransplantation. N Engl J Med. 2022;386:1889\u201398.","journal-title":"N Engl J Med"},{"key":"2594_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30916-6","volume":"8","author":"DR Principe","year":"2018","unstructured":"Principe DR, Overgaard NH, Park AJ, Diaz AM, Torres C, Mckinney R, et al. KRAS(g12d) and TP53(r167h) cooperate to induce pancreatic ductal adenocarcinoma in sus scrofa pigs. Sci Rep. 2018;8:12548.","journal-title":"Sci Rep"},{"key":"2594_CR58","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jvir.2024.01.005","volume":"35","author":"J Lee","year":"2024","unstructured":"Lee J, Boas FE, Duran-Struuck R, Gaba RC, Schachtschneider KM, Comin-Anduix B, et al. Pigs as clinically relevant models for synergizing interventional oncology and immunotherapy. J Vasc Interv Radiol. 2024;35:809\u201317.","journal-title":"J Vasc Interv Radiol"},{"key":"2594_CR59","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41573-021-00210-8","volume":"20","author":"EE Patton","year":"2021","unstructured":"Patton EE, Zon LI, Langenau DM. Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials. Nat Rev Drug Discov. 2021;20:611\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"2594_CR60","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1161\/CIRCULATIONAHA.123.064489","volume":"149","author":"B Li","year":"2024","unstructured":"Li B, Liu F, Chen X, Chen T, Zhang J, Liu Y, et al. FARS2 deficiency causes cardiomyopathy by disrupting mitochondrial homeostasis and the mitochondrial quality control system. Circulation. 2024;149:1268\u201384.","journal-title":"Circulation"},{"key":"2594_CR61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10522-018-9780-6","volume":"20","author":"J Van Houcke","year":"2019","unstructured":"Van Houcke J, Geeraerts E, Vanhunsel S, Beckers A, Noterdaeme L, Christiaens M, et al. Extensive growth is followed by neurodegenerative pathology in the continuously expanding adult zebrafish retina. Biogerontology. 2019;20:109\u201325.","journal-title":"Biogerontology"},{"key":"2594_CR62","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrc3972","volume":"15","author":"RM Hoffman","year":"2015","unstructured":"Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015;15:451\u20132.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR63","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.21873\/anticanres.16622","volume":"43","author":"T Higuchi","year":"2023","unstructured":"Higuchi T, Yamamoto N, Hayashi K, Miwa S, Igarashi K, Tsuchiya H, et al. High clinical concordance of drug resistance in patient-derived orthotopic xenograft (PDOX) mouse models: first step to validated precise individualized cancer chemotherapy. Anticancer Res. 2023;43:4277\u201384.","journal-title":"Anticancer Res"},{"key":"2594_CR64","doi-asserted-by":"crossref","unstructured":"Yildiz M, Romano A, Xanthoulea S. Murine xenograft models as preclinical tools in endometrial cancer research. Cancers. 2024;16(23):3994.","DOI":"10.3390\/cancers16233994"},{"key":"2594_CR65","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/2767-9764.CRC-25-0008","volume":"5","author":"Y Sheng","year":"2025","unstructured":"Sheng Y, Xie Z, Wang J, Yang X, Yao M, Qian W, et al. Impact of subcutaneous versus orthotopic implantations on patient-derived xenograft transcriptomic profiles. Cancer Res Commun. 2025;5:871\u201380.","journal-title":"Cancer Res Commun"},{"key":"2594_CR66","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ame2.12399","volume":"8","author":"J Gao","year":"2025","unstructured":"Gao J, Zhao Y, Wang Z, Liu F, Chen X, Mo J, et al. Single-cell transcriptomic sequencing identifies subcutaneous patient-derived xenograft recapitulated medulloblastoma. Anim Model Exp Med. 2025;8:458\u201372.","journal-title":"Anim Model Exp Med"},{"key":"2594_CR67","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-16-1237","volume":"23","author":"JF Liu","year":"2017","unstructured":"Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res. 2017;23:1263\u201373.","journal-title":"Clin Cancer Res"},{"key":"2594_CR68","first-page":"23","volume":"8","author":"R Qin","year":"2025","unstructured":"Qin R, Liang Y, Zhou F. Advances in the application of patient-derived xenograft models in acute leukemia resistance. Cancer Drug Resist. 2025;8:23.","journal-title":"Cancer Drug Resist"},{"key":"2594_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4048\/jbc.2023.0177","volume":"27","author":"Y Her","year":"2024","unstructured":"Her Y, Yun J, Son HY, Heo W, Kim JI, Moon HG. Potential perturbations of critical cancer-regulatory genes in triple-negative breast cancer cells within the humanized microenvironment of patient-derived xenograft models. J Breast Cancer. 2024;27:37\u201353.","journal-title":"J Breast Cancer"},{"key":"2594_CR70","doi-asserted-by":"crossref","unstructured":"Collins AT, Lang SH. A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine. PeerJ. 2018;6:e5981.","DOI":"10.7717\/peerj.5981"},{"key":"2594_CR71","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","volume":"26","author":"RA Vaubel","year":"2020","unstructured":"Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, et al. Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res. 2020;26:1094\u2013104.","journal-title":"Clin Cancer Res"},{"key":"2594_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100759","volume":"4","author":"S Domanskyi","year":"2024","unstructured":"Domanskyi S, Srivastava A, Kaster J, Li H, Herlyn M, Rubinstein JC, et al. Nextflow pipeline for visium and H&E data from patient-derived xenograft samples. Cell Rep Methods. 2024;4:100759.","journal-title":"Cell Rep Methods"},{"key":"2594_CR73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10911-021-09485-4","volume":"26","author":"Q Juppet","year":"2021","unstructured":"Juppet Q, De Martino F, Marcandalli E, Weigert M, Burri O, Unser M, et al. Deep learning enables individual xenograft cell classification in histological images by analysis of contextual features. J Mammary Gland Biol Neoplasia. 2021;26:101\u201312.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"2594_CR74","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023;24:695\u2013713.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2594_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70059","volume":"6","author":"A Gu","year":"2025","unstructured":"Gu A, Li J, Li MY, Liu Y. Patient-derived xenograft model in cancer: establishment and applications. MedComm. 2025;6:e70059.","journal-title":"MedComm"},{"key":"2594_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25177-3","volume":"12","author":"H Sun","year":"2021","unstructured":"Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021;12:5086.","journal-title":"Nat Commun"},{"key":"2594_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29444-9","volume":"13","author":"S Mirhadi","year":"2022","unstructured":"Mirhadi S, Tam S, Li Q, Moghal N, Pham NA, Tong J, et al. Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. Nat Commun. 2022;13:1811.","journal-title":"Nat Commun"},{"key":"2594_CR78","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12967-025-06787-7","volume":"23","author":"P Guo","year":"2025","unstructured":"Guo P, Fang H, Shi H, Zhang J, Song G, Fan C, et al. Metabolic, transcriptomic, and proteomic adaptations in pancreatic ductal adenocarcinoma-patient derived xenograft models across serial passages. J Transl Med. 2025;23:732.","journal-title":"J Transl Med"},{"key":"2594_CR79","doi-asserted-by":"crossref","unstructured":"Rao AD, Cai L, Snyman M, Walsdorf RE, Li X, Wix SN, Gard G, Brown AB, Kim J, Santos PJ, et al. Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts. Nat Metab. 2025;7(8):1703\u201313.","DOI":"10.1038\/s42255-025-01338-2"},{"key":"2594_CR80","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41571-025-01003-3","volume":"22","author":"E Boxer","year":"2025","unstructured":"Boxer E, Feigin N, Tschernichovsky R, Darnell NG, Greenwald AR, Hoefflin R, et al. Emerging clinical applications of single-cell RNA sequencing in oncology. Nat Rev Clin Oncol. 2025;22:315\u201326.","journal-title":"Nat Rev Clin Oncol"},{"key":"2594_CR81","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1182\/blood.2024026482","volume":"145","author":"YY Ding","year":"2025","unstructured":"Ding YY, Sussman JH, Madden K, Loftus JP, Chen RK, Falkenstein CD, et al. Targeting senescent stemlike subpopulations in Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2025;145:1195\u2013210.","journal-title":"Blood"},{"key":"2594_CR82","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1593\/neo.13922","volume":"15","author":"M Mattie","year":"2013","unstructured":"Mattie M, Christensen A, Chang MS, Yeh W, Said S, Shostak Y, et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia. 2013;15:1138\u201350.","journal-title":"Neoplasia"},{"key":"2594_CR83","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41592-023-02144-y","volume":"21","author":"S Peidli","year":"2024","unstructured":"Peidli S, Green TD, Shen C, Gross T, Min J, Garda S, et al. Scperturb: harmonized single-cell perturbation data. Nat Methods. 2024;21:531\u201340.","journal-title":"Nat Methods"},{"key":"2594_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53163-y","volume":"15","author":"U Perron","year":"2024","unstructured":"Perron U, Grassi E, Chatzipli A, Viviani M, Karakoc E, Trastulla L, et al. Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts. Nat Commun. 2024;15:9139.","journal-title":"Nat Commun"},{"key":"2594_CR85","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1158\/0008-5472.CAN-17-0582","volume":"77","author":"TF Meehan","year":"2017","unstructured":"Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, et al. PDX-MI: minimal information for patient-derived tumor xenograft models. Cancer Res. 2017;77:e62\u20136.","journal-title":"Cancer Res"},{"key":"2594_CR86","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc.2016.140","volume":"17","author":"AT Byrne","year":"2017","unstructured":"Byrne AT, Alferez DG, Amant F, Annibali D, Arribas J, Biankin AV, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17:254\u201368.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR87","doi-asserted-by":"crossref","unstructured":"Eguchi K, Shimizu T, Kato D, Furuta Y, Kamiota S, Ban H, Ymamoto S, Yokoyama A, Kitabayashi I. Preclinical evaluation of a novel orally bioavailable menin - MLL interaction inhibitor, DSP-5336, for the treatment of acute leukemia patients with MLL - rearrangement or NPM1 mutation. Blood. 2021;138(Supplement 1):3339.","DOI":"10.1182\/blood-2021-152050"},{"key":"2594_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00520-8","volume":"13","author":"H Pan","year":"2024","unstructured":"Pan H, Tian Y, Pei S, Yang W, Zhang Y, Gu Z, et al. Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer. Exp Hematol Oncol. 2024;13:52.","journal-title":"Exp Hematol Oncol"},{"key":"2594_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03405-8","volume":"20","author":"S Abdolahi","year":"2022","unstructured":"Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh AH, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20:206.","journal-title":"J Transl Med"},{"key":"2594_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrc3944","volume":"15","author":"S Aparicio","year":"2015","unstructured":"Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015;15:311\u20136.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR91","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21:1318\u201325.","journal-title":"Nat Med"},{"key":"2594_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25175-5","volume":"12","author":"GP Risbridger","year":"2021","unstructured":"Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, et al. The mural collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat Commun. 2021;12:5049.","journal-title":"Nat Commun"},{"key":"2594_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-018-0329-5","volume":"38","author":"F Zhang","year":"2018","unstructured":"Zhang F, Wang W, Long Y, Liu H, Cheng J, Guo L, et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun. 2018;38:60.","journal-title":"Cancer Commun"},{"key":"2594_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101427","volume":"21","author":"MJ Cotler","year":"2022","unstructured":"Cotler MJ, Ramadi KB, Hou X, Christodoulopoulos E, Ahn S, Bashyam A, et al. Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors. Transl Oncol. 2022;21:101427.","journal-title":"Transl Oncol"},{"key":"2594_CR95","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.apsb.2023.09.015","volume":"14","author":"L Sun","year":"2024","unstructured":"Sun L, Wan AH, Yan S, Liu R, Li J, Zhou Z, et al. A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance. Acta Pharm Sin B. 2024;14:223\u201340.","journal-title":"Acta Pharm Sin B"},{"key":"2594_CR96","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","volume":"6","author":"MR Girotti","year":"2016","unstructured":"Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 2016;6:286\u201399.","journal-title":"Cancer Discov"},{"key":"2594_CR97","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508\u201323.","journal-title":"Cancer Discov"},{"key":"2594_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102019","volume":"86","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019.","journal-title":"Cancer Treat Rev"},{"key":"2594_CR99","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","volume":"26","author":"M Wong","year":"2020","unstructured":"Wong M, Mayoh C, Lau L, Khuong-Quang DA, Pinese M, Kumar A, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26:1742\u201353.","journal-title":"Nat Med"},{"key":"2594_CR100","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/0008-5472.CAN-24-1703","volume":"85","author":"A Shea","year":"2025","unstructured":"Shea A, Eyal-Lubling Y, Guerrero-Romero D, Manzano GR, Greenwood W, O\u2019Reilly M, et al. Modeling drug responses and evolutionary dynamics using patient-derived xenografts reveals precision medicine strategies for triple-negative breast cancer. Cancer Res. 2025;85:567\u201384.","journal-title":"Cancer Res"},{"key":"2594_CR101","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-22-0948","volume":"82","author":"XY Woo","year":"2022","unstructured":"Woo XY, Srivastava A, Mack PC, Graber JH, Sanderson BJ, Lloyd MW, et al. A genomically and clinically annotated patient-derived xenograft resource for preclinical research in non-small cell lung cancer. Cancer Res. 2022;82:4126\u201338.","journal-title":"Cancer Res"},{"key":"2594_CR102","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 2024;187:184\u2013203.","journal-title":"Cell"},{"key":"2594_CR103","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 2022;28:2171\u201382.","journal-title":"Nat Med"},{"key":"2594_CR104","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135\u201361.","journal-title":"Cancer Discov"},{"key":"2594_CR105","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, et al. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov. 2022;12:1676\u201389.","journal-title":"Cancer Discov"},{"key":"2594_CR106","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/2159-8290.CD-22-0158","volume":"12","author":"A Weiss","year":"2022","unstructured":"Weiss A, Lorthiois E, Barys L, Beyer KS, Bomio-Confaglia C, Burks H, et al. Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12c. Cancer Discov. 2022;12:1500\u201317.","journal-title":"Cancer Discov"},{"key":"2594_CR107","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1158\/2159-8290.CD-20-0872","volume":"11","author":"G Lalazar","year":"2021","unstructured":"Lalazar G, Requena D, Ramos-Espiritu L, Ng D, Bhola PD, de Jong YP, et al. Identification of novel therapeutic targets for fibrolamellar carcinoma using patient-derived xenografts and direct-from-patient screening. Cancer Discov. 2021;11:2544\u201363.","journal-title":"Cancer Discov"},{"key":"2594_CR108","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.21873\/invivo.12997","volume":"36","author":"N Masaki","year":"2022","unstructured":"Masaki N, Aoki Y, Kubota Y, Obara K, Miyazaki J, Hoffman RM. Chloroquine combined with rapamycin arrests tumor growth in a patient-derived orthotopic xenograft (PDOX) mouse model of dedifferentiated liposarcoma. In Vivo. 2022;36:2630\u20137.","journal-title":"In Vivo"},{"key":"2594_CR109","doi-asserted-by":"publisher","first-page":"217","DOI":"10.21873\/cgp.20182","volume":"17","author":"K Igarashi","year":"2020","unstructured":"Igarashi K, Kawaguchi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, et al. A novel anionic-phosphate-platinum complex effectively targets a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model. Cancer Genomics Proteomics. 2020;17:217\u201323.","journal-title":"Cancer Genomics Proteomics"},{"key":"2594_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2024.100744","volume":"47","author":"JR Tseng","year":"2024","unstructured":"Tseng JR, Hsu CL, Hsieh HH, Ho KC, Chung YH, Wu CY. The synergy of (177)Lu-FAPI-46 with tyrosine kinase inhibitor in a sarcoma patient-derived xenograft mouse model. Biomed J. 2024;47:100744.","journal-title":"Biomed J"},{"key":"2594_CR111","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41374-021-00704-4","volume":"102","author":"TP Safaric","year":"2022","unstructured":"Safaric TP, Segovia D, Jevtic S, Ramirez D, Lyons SK, Sordella R. Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma. Lab Invest. 2022;102:1038\u201349.","journal-title":"Lab Invest"},{"key":"2594_CR112","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1158\/1078-0432.CCR-23-4072","volume":"30","author":"J Martinez-Quintanilla","year":"2024","unstructured":"Martinez-Quintanilla J, Cabot D, Sabia D, Arques O, Verges J, Chicote I, et al. Precision oncology and systemic targeted therapy in pseudomyxoma peritonei. Clin Cancer Res. 2024;30:4082\u201399.","journal-title":"Clin Cancer Res"},{"key":"2594_CR113","doi-asserted-by":"crossref","unstructured":"Coussens NP, Teicher BA. Rare tumors, real targets: patient-derived models for the discovery and validation of precision therapies. Expert Opin Ther Targets. 2025;29(8):509\u201315.","DOI":"10.1080\/14728222.2025.2551116"},{"key":"2594_CR114","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","volume":"82","author":"AV Sorokin","year":"2022","unstructured":"Sorokin AV, Kanikarla MP, Bitner L, Syed M, Woods M, Manyam G, et al. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6. Cancer Res. 2022;82:3335\u201344.","journal-title":"Cancer Res"},{"key":"2594_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13:4.","journal-title":"J Hematol Oncol"},{"key":"2594_CR116","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-11-0061","volume":"1","author":"C Nardella","year":"2011","unstructured":"Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. The APL paradigm and the \u201cco-clinical trial\u201d project. Cancer Discov. 2011;1:108\u201316.","journal-title":"Cancer Discov"},{"key":"2594_CR117","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/2159-8290.CD-23-0838","volume":"14","author":"TP Diperi","year":"2024","unstructured":"Diperi TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, et al. Co-clinical trial of novel bispecific anti-HER2 antibody zanidatamab in patient-derived xenografts. Cancer Discov. 2024;14:828\u201345.","journal-title":"Cancer Discov"},{"key":"2594_CR118","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1158\/1078-0432.CCR-22-3861","volume":"29","author":"S Yagishita","year":"2023","unstructured":"Yagishita S, Nishikawa T, Yoshida H, Shintani D, Sato S, Miwa M, et al. Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy. Clin Cancer Res. 2023;29:2239\u201349.","journal-title":"Clin Cancer Res"},{"key":"2594_CR119","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","volume":"14","author":"R van der Meel","year":"2019","unstructured":"van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder W, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14:1007\u201317.","journal-title":"Nat Nanotechnol"},{"key":"2594_CR120","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.medj.2022.12.001","volume":"4","author":"P Zhang","year":"2023","unstructured":"Zhang P, Xiao Y, Sun X, Lin X, Koo S, Yaremenko AV, et al. Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects. Med. 2023;4:147\u201367.","journal-title":"Med"},{"key":"2594_CR121","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2019.05.044","volume":"305","author":"K Park","year":"2019","unstructured":"Park K. The beginning of the end of the nanomedicine hype. J Control Release. 2019;305:221\u20132.","journal-title":"J Control Release"},{"key":"2594_CR122","doi-asserted-by":"crossref","unstructured":"Joyce P, Allen CJ, Alonso MJ, Ashford M, Bradbury MS, Germain M, Kavallaris M, Langer R, Lammers T, Peracchia MT, et al. A translational framework to DELIVER nanomedicines to the clinic. Nat Nanotechnol. 2024;19(11):1597\u2013611.","DOI":"10.1038\/s41565-024-01754-7"},{"key":"2594_CR123","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41551-018-0314-y","volume":"2","author":"J Ioannidis","year":"2018","unstructured":"Ioannidis J, Kim B, Trounson A. How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nat Biomed Eng. 2018;2:797\u2013809.","journal-title":"Nat Biomed Eng"},{"key":"2594_CR124","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41568-022-00496-9","volume":"22","author":"SN Bhatia","year":"2022","unstructured":"Bhatia SN, Chen X, Dobrovolskaia MA, Lammers T. Cancer nanomedicine. Nat Rev Cancer. 2022;22:550\u20136.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR125","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41565-020-00817-9","volume":"16","author":"W Jiang","year":"2021","unstructured":"Jiang W, Wang Y, Wargo JA, Lang FF, Kim B. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021;16:6\u201315.","journal-title":"Nat Nanotechnol"},{"key":"2594_CR126","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1158\/0008-5472.CAN-23-3031","volume":"84","author":"MW Kunkel","year":"2024","unstructured":"Kunkel MW, Coussens NP, Morris J, Taylor RC, Dexheimer TS, Jones EM, et al. HTS384 NCI60: the next phase of the NCI60 screen. Cancer Res. 2024;84:2403\u201316.","journal-title":"Cancer Res"},{"key":"2594_CR127","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.trecan.2020.03.012","volume":"6","author":"J Xiao","year":"2020","unstructured":"Xiao J, Glasgow E, Agarwal S. Zebrafish xenografts for drug discovery and personalized medicine. Trends Cancer. 2020;6:569\u201379.","journal-title":"Trends Cancer"},{"key":"2594_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"key":"2594_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86384-2","volume":"15","author":"JJ Caumanns","year":"2025","unstructured":"Caumanns JJ, Li S, Meersma GJ, Duiker EW, van der Zee AGJ, Wisman GBA, et al. Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts. Sci Rep. 2025;15:4434.","journal-title":"Sci Rep"},{"key":"2594_CR130","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41388-017-0018-x","volume":"37","author":"A Blomme","year":"2018","unstructured":"Blomme A, Van Simaeys G, Doumont G, Costanza B, Bellier J, Otaka Y, et al. Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases. Oncogene. 2018;37:1237\u201350.","journal-title":"Oncogene"},{"key":"2594_CR131","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41588-020-00750-6","volume":"53","author":"XY Woo","year":"2021","unstructured":"Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021;53:86\u201399.","journal-title":"Nat Genet"},{"key":"2594_CR132","doi-asserted-by":"crossref","unstructured":"Hyun S, Han Y, Moon JY, Suh YA, Yun WG, Kwon W, Lee JE, Kim D, Ku JL, Jang JY, et al. Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma. Cancer Commun. 2024;44(8):921\u20135.","DOI":"10.1002\/cac2.12585"},{"key":"2594_CR133","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41586-021-03273-0","volume":"592","author":"C Zheng","year":"2021","unstructured":"Zheng C, Hu Y, Sakurai M, Pinzon-Arteaga CA, Li J, Wei Y, et al. Cell competition constitutes a barrier for interspecies chimerism. Nature. 2021;592:272\u20136.","journal-title":"Nature"},{"key":"2594_CR134","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.stem.2024.07.010","volume":"31","author":"E Ballard","year":"2024","unstructured":"Ballard E, Sakurai M, Yu L, Liu L, Oura S, Huang J, et al. Incompatibility in cell adhesion constitutes a barrier to interspecies chimerism. Cell Stem Cell. 2024;31:1419\u201326.","journal-title":"Cell Stem Cell"},{"key":"2594_CR135","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1101\/pdb.top073585","volume":"2014","author":"LD Shultz","year":"2014","unstructured":"Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014;2014:694\u2013708.","journal-title":"Cold Spring Harb Protoc"},{"key":"2594_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209034","volume":"13","author":"M Wunderlich","year":"2018","unstructured":"Wunderlich M, Chou FS, Sexton C, Presicce P, Chougnet CA, Aliberti J, et al. Improved multilineage human hematopoietic reconstitution and function in NSGS mice. PLoS ONE. 2018;13:e0209034.","journal-title":"PLoS ONE"},{"key":"2594_CR137","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.biopha.2017.11.024","volume":"97","author":"JK Liao","year":"2018","unstructured":"Liao JK, Zhou B, Zhuang XM, Zhuang PL, Zhang DM, Chen WL. Cancer-associated fi broblasts confer cisplatin resistance of tongue cancer via autophagy activation. Biomed Pharmacother. 2018;97:1341\u20138.","journal-title":"Biomed Pharmacother"},{"key":"2594_CR138","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12859-018-2353-5","volume":"19","author":"R Kluin","year":"2018","unstructured":"Kluin R, Kemper K, Kuilman T, de Ruiter JR, Iyer V, Forment JV, et al. XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data. BMC Bioinformatics. 2018;19:366.","journal-title":"BMC Bioinformatics"},{"key":"2594_CR139","doi-asserted-by":"publisher","first-page":"i172","DOI":"10.1093\/bioinformatics\/bts236","volume":"28","author":"T Conway","year":"2012","unstructured":"Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. Xenome\u2013a tool for classifying reads from xenograft samples. Bioinformatics. 2012;28:i172\u20138.","journal-title":"Bioinformatics"},{"key":"2594_CR140","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"2594_CR141","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41587-021-00830-w","volume":"40","author":"DM Cable","year":"2022","unstructured":"Cable DM, Murray E, Zou LS, Goeva A, Macosko EZ, Chen F, et al. Robust decomposition of cell type mixtures in spatial transcriptomics. Nat Biotechnol. 2022;40:517\u201326.","journal-title":"Nat Biotechnol"},{"key":"2594_CR142","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ccell.2021.01.011","volume":"39","author":"EE Patton","year":"2021","unstructured":"Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, et al. Melanoma models for the next generation of therapies. Cancer Cell. 2021;39:610\u201331.","journal-title":"Cancer Cell"},{"key":"2594_CR143","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature13952","volume":"518","author":"P Eirew","year":"2015","unstructured":"Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518:422\u20136.","journal-title":"Nature"},{"key":"2594_CR144","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ng.3967","volume":"49","author":"U Ben-David","year":"2017","unstructured":"Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49:1567\u201375.","journal-title":"Nat Genet"},{"key":"2594_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43373-1","volume":"14","author":"F He","year":"2023","unstructured":"He F, Bandyopadhyay AM, Klesse LJ, Rogojina A, Chun SH, Butler E, et al. Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer. Nat Commun. 2023;14:7600.","journal-title":"Nat Commun"},{"key":"2594_CR146","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1038\/s41467-024-47547-3","volume":"15","author":"RE Hynds","year":"2024","unstructured":"Hynds RE, Huebner A, Pearce DR, Hill MS, Akarca AU, Moore DA, et al. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models. Nat Commun. 2024;15:4653.","journal-title":"Nat Commun"},{"key":"2594_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00908-0","volume":"7","author":"Y Yao","year":"2022","unstructured":"Yao Y, Wang Y, Chen L, Tian Z, Yang G, Wang R, et al. Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC. Signal Transduct Target Ther. 2022;7:73.","journal-title":"Signal Transduct Target Ther"},{"key":"2594_CR148","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41375-023-02095-5","volume":"38","author":"H Playa-Albinyana","year":"2024","unstructured":"Playa-Albinyana H, Arenas F, Royo R, Giro A, Lopez-Oreja I, Aymerich M, et al. Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to richter transformation. Leukemia. 2024;38:557\u201369.","journal-title":"Leukemia"},{"key":"2594_CR149","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1158\/0008-5472.CAN-19-0349","volume":"79","author":"AS Mer","year":"2019","unstructured":"Mer AS, Ba-Alawi W, Smirnov P, Wang YX, Brew B, Ortmann J, et al. Integrative pharmacogenomics analysis of patient-derived xenografts. Cancer Res. 2019;79:4539\u201350.","journal-title":"Cancer Res"},{"key":"2594_CR150","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ng.3967","volume":"49","author":"U Ben-David","year":"2017","unstructured":"Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49:1567\u201375.","journal-title":"Nat Genet"},{"key":"2594_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00268-6","volume":"6","author":"ACH Hoge","year":"2022","unstructured":"Hoge ACH, Getz M, Zimmer A, Ko M, Raz L, Beroukhim R, et al. DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis Oncol. 2022;6:30.","journal-title":"NPJ Precis Oncol"},{"key":"2594_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01955-5","volume":"9","author":"Z Liu","year":"2024","unstructured":"Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A, et al. Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther. 2024;9:270.","journal-title":"Signal Transduct Target Ther"},{"key":"2594_CR153","doi-asserted-by":"crossref","unstructured":"Mahmoud A, Ganesh K. Mouse models of metastasis and dormancy. Cold Spring Harb Perspect Med. 2024;14(8):a041386.","DOI":"10.1101\/cshperspect.a041386"},{"key":"2594_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81832-1","volume":"11","author":"AM Baschnagel","year":"2021","unstructured":"Baschnagel AM, Kaushik S, Durmaz A, Goldstein S, Ong IM, Abel L, et al. Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. Sci Rep. 2021;11:2520.","journal-title":"Sci Rep"},{"key":"2594_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01369-9","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu L, Cui J, Zhao Y, Liu X, Chen L, Xia Y, et al. KDM6a-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. Mol Cancer. 2021;20:77.","journal-title":"Mol Cancer"},{"key":"2594_CR156","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s43018-021-00297-3","volume":"3","author":"J Dai","year":"2022","unstructured":"Dai J, Cimino PJ, Gouin KR, Grzelak CA, Barrett A, Lim AR, et al. Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nat Cancer. 2022;3:25\u201342.","journal-title":"Nat Cancer"},{"key":"2594_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02833-8","volume":"42","author":"L Xie","year":"2023","unstructured":"Xie L, Qiu S, Lu C, Gu C, Wang J, Lv J, et al. Gastric cancer-derived LBP promotes liver metastasis by driving intrahepatic fibrotic pre-metastatic niche formation. J Exp Clin Cancer Res. 2023;42:258.","journal-title":"J Exp Clin Cancer Res"},{"key":"2594_CR158","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41556-023-01241-6","volume":"25","author":"F Qu","year":"2023","unstructured":"Qu F, Brough SC, Michno W, Madubata CJ, Hartmann GG, Puno A, et al. Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis. Nat Cell Biol. 2023;25:1506\u201319.","journal-title":"Nat Cell Biol"},{"key":"2594_CR159","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","volume":"160","author":"B Heinrich","year":"2021","unstructured":"Heinrich B, Brown ZJ, Diggs LP, Vormehr M, Ma C, Subramanyam V, et al. Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice. Gastroenterology. 2021;160:331\u201345.","journal-title":"Gastroenterology"},{"key":"2594_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.128848","volume":"258","author":"Y Hu","year":"2024","unstructured":"Hu Y, Xie Q, Zhao J, Yang R, Qin J, Li H, et al. Interaction between the EPHB2 receptor and EFNB1 ligand drives gastric cancer invasion and metastasis via the wnt\/beta-catenin\/FAK pathway. Int J Biol Macromol. 2024;258:128848.","journal-title":"Int J Biol Macromol"},{"key":"2594_CR161","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41417-025-00878-9","volume":"32","author":"Y Mao","year":"2025","unstructured":"Mao Y, Hu Y, Meng H, Qin J, An Q, Zhang C, et al. Fxyd5 regulates gastric cancer cell metastasis and drug resistance by EMT modulation. Cancer Gene Ther. 2025;32:318\u201326.","journal-title":"Cancer Gene Ther"},{"key":"2594_CR162","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41590-019-0416-z","volume":"20","author":"TM Allen","year":"2019","unstructured":"Allen TM, Brehm MA, Bridges S, Ferguson S, Kumar P, Mirochnitchenko O, et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat Immunol. 2019;20:770\u20134.","journal-title":"Nat Immunol"},{"key":"2594_CR163","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/cmi.2017.106","volume":"15","author":"T Yaguchi","year":"2018","unstructured":"Yaguchi T, Kobayashi A, Inozume T, Morii K, Nagumo H, Nishio H, et al. Human PBMC-transferred murine MHC class i\/II-deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol. 2018;15:953\u201362.","journal-title":"Cell Mol Immunol"},{"key":"2594_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173754","volume":"12","author":"Y Zeng","year":"2017","unstructured":"Zeng Y, Liu B, Rubio MT, Wang X, Ojcius DM, Tang R, et al. Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells. PLoS ONE. 2017;12:e0173754.","journal-title":"PLoS ONE"},{"key":"2594_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179239","volume":"12","author":"Y Kametani","year":"2017","unstructured":"Kametani Y, Katano I, Miyamoto A, Kikuchi Y, Ito R, Muguruma Y, et al. NOG-hIL-4-tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination. PLoS ONE. 2017;12:e0179239.","journal-title":"PLoS ONE"},{"key":"2594_CR166","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01394-21","volume":"96","author":"L Holguin","year":"2022","unstructured":"Holguin L, Echavarria L, Burnett JC. Novel humanized peripheral blood mononuclear cell mouse model with delayed onset of graft-versus-host disease for preclinical HIV research. J Virol. 2022;96:e0139421.","journal-title":"J Virol"},{"key":"2594_CR167","doi-asserted-by":"crossref","unstructured":"Panisello C, Aschero R, Martinez-Moreno A, Roca HH, Falgas A, Gonzalez-Navarro EA, Carabelli J, Pradenas E, Lazaro-Diez M, Prado JG, et al. NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host disease. J Immunother Cancer. 2024;12(10):e009198.","DOI":"10.1136\/jitc-2024-009198"},{"key":"2594_CR168","doi-asserted-by":"crossref","unstructured":"Stocks H, Van Cleemput J, Vandekerckhove, L, Wullaert A. Advances in human myeloid-engrafting NSG-SGM3 and MISTRG mice. Trends Immunol. 2025;46(10):662\u20135.","DOI":"10.1016\/j.it.2025.07.011"},{"key":"2594_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03799-w","volume":"15","author":"R Ito","year":"2024","unstructured":"Ito R, Ohno Y, Mu Y, Ka Y, Ito S, Emi-Sugie M, et al. Improvement of multilineage hematopoiesis in hematopoietic stem cell-transferred c-kit mutant NOG-EXL humanized mice. Stem Cell Res Ther. 2024;15:182.","journal-title":"Stem Cell Res Ther"},{"key":"2594_CR170","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1016\/j.cell.2025.03.022","volume":"188","author":"Y Hou","year":"2025","unstructured":"Hou Y, Wu Y, Cao Y, Hu X, Sun Y, Wang H, et al. Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease. Cell. 2025;188:3030\u201344.","journal-title":"Cell"},{"key":"2594_CR171","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01476-x","volume":"23","author":"SD Scherer","year":"2021","unstructured":"Scherer SD, Riggio AI, Haroun F, Derose YS, Ekiz HA, Fujita M, et al. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. Breast Cancer Res. 2021;23:100.","journal-title":"Breast Cancer Res"},{"key":"2594_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143695","author":"C Yan","year":"2023","unstructured":"Yan C, Nebhan CA, Saleh N, Shattuck-Brandt R, Chen SC, Ayers GD, et al. Generation of orthotopic patient-derived xenografts in humanized mice for evaluation of emerging targeted therapies and immunotherapy combinations for melanoma. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15143695.","journal-title":"Cancers (Basel)"},{"key":"2594_CR173","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1158\/2159-8290.CD-22-0412","volume":"13","author":"C Stossel","year":"2023","unstructured":"Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick GY, Halperin S, et al. Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting. Cancer Discov. 2023;13:1826\u201343.","journal-title":"Cancer Discov"},{"key":"2594_CR174","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40164-024-00520-8","volume":"13","author":"H Pan","year":"2024","unstructured":"Pan H, Tian Y, Pei S, Yang W, Zhang Y, Gu Z, et al. Combination of percutaneous thermal ablation and adoptive th9 cell transfer therapy against non-small cell lung cancer. Exp Hematol Oncol. 2024;13:52.","journal-title":"Exp Hematol Oncol"},{"key":"2594_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113783","volume":"383","author":"X Yin","year":"2025","unstructured":"Yin X, Zhao X, Shen Y, Xie W, He C, Guo J, et al. Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma. J Control Release. 2025;383:113783.","journal-title":"J Control Release"},{"key":"2594_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18498","volume":"9","author":"Y Li","year":"2023","unstructured":"Li Y, Li Y, Yang Y, Deng Y, Ni X, Zhao B, et al. Synergistic efficacy of PI3kdelta inhibitor with anti-PD-1 mabs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer. Heliyon. 2023;9:e18498.","journal-title":"Heliyon"},{"key":"2594_CR177","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-18-3440","volume":"25","author":"L Lazzari","year":"2019","unstructured":"Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P, et al. Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer. Clin Cancer Res. 2019;25:6243\u201359.","journal-title":"Clin Cancer Res"},{"key":"2594_CR178","doi-asserted-by":"crossref","unstructured":"Jiang TY, Pan YF, Wan ZH, Lin YK, Zhu B, Yuan ZG, Ma YH, Shi YY, Zeng TM, Dong LW, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Sci Transl Med. 2020;12(562):eaay0152.","DOI":"10.1126\/scitranslmed.aay0152"},{"key":"2594_CR179","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1078-0432.CCR-23-0873","volume":"30","author":"CR Schott","year":"2024","unstructured":"Schott CR, Koehne AL, Sayles LC, Young EP, Luck C, Yu K, et al. Osteosarcoma PDX-derived cell line models for preclinical drug evaluation demonstrate metastasis inhibition by dinaciclib through a genome-targeted approach. Clin Cancer Res. 2024;30:849\u201364.","journal-title":"Clin Cancer Res"},{"key":"2594_CR180","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.stem.2023.05.012","volume":"30","author":"HHN Yan","year":"2023","unstructured":"Yan HHN, Chan AS, Lai FPL, Leung SY. Organoid cultures for cancer modeling. Cell Stem Cell. 2023;30:917\u201337.","journal-title":"Cell Stem Cell"},{"key":"2594_CR181","doi-asserted-by":"crossref","unstructured":"Wu Y, Sun R, Zengin G, Ren S, Li M. Tumor organoids: breakthroughs in clinical decision making, drug development, and translational advances beyond conventional models. Med Research. 2025.","DOI":"10.1002\/mdr2.70048"},{"key":"2594_CR182","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc. 2020;15:3380\u2013409.","journal-title":"Nat Protoc"},{"key":"2594_CR183","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perreard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56:1531\u201351.","journal-title":"Exp Mol Med"},{"key":"2594_CR184","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","volume":"24","author":"R Polak","year":"2024","unstructured":"Polak R, Zhang ET, Kuo CJ. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat Rev Cancer. 2024;24:523\u201339.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR185","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. Med. 2024;5:1351\u201377.","journal-title":"Med"},{"key":"2594_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101627","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Li S, Zhu L, Huang M, Xie Y, Song X, et al. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Cell Rep Med. 2024;5:101627.","journal-title":"Cell Rep Med"},{"key":"2594_CR187","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41591-024-03489-3","volume":"31","author":"M Verstegen","year":"2025","unstructured":"Verstegen M, Coppes RP, Beghin A, De Coppi P, Gerli M, de Graeff N, et al. Clinical applications of human organoids. Nat Med. 2025;31:409\u201321.","journal-title":"Nat Med"},{"key":"2594_CR188","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1126\/science.aaw7894","volume":"364","author":"SE Park","year":"2019","unstructured":"Park SE, Georgescu A, Huh D. Organoids-on-a-chip. Science. 2019;364:960\u20135.","journal-title":"Science"},{"key":"2594_CR189","first-page":"263","volume":"2","author":"E Wang","year":"2022","unstructured":"Wang E, Xiang K, Zhang Y, Wang XF. Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): new opportunities in establishing faithful pre-clinical cancer models. J Natl Cancer Cent. 2022;2:263\u201376.","journal-title":"J Natl Cancer Cent"},{"key":"2594_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00478-6","volume":"7","author":"AT Sengal","year":"2023","unstructured":"Sengal AT, Bonazzi V, Smith D, Moiola CP, Lourie R, Rogers R, et al. Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition. NPJ Precis Oncol. 2023;7:127.","journal-title":"NPJ Precis Oncol"},{"key":"2594_CR191","doi-asserted-by":"crossref","unstructured":"L Hmussaar, K., Oka, R., Espejo Valle-Inclan, J., Smits, M.H.H., Wardak, H., Korving, J., Begthel, H., Proost, N., van de Ven, M., and Kranenburg, O.W., et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell Stem Cell. 2021;28:1380\u20131396.","DOI":"10.1016\/j.stem.2021.03.012"},{"key":"2594_CR192","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nbt.3837","volume":"35","author":"KP O'Rourke","year":"2017","unstructured":"O\u2019Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, et al. Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol. 2017;35:577\u201382.","journal-title":"Nat Biotechnol"},{"key":"2594_CR193","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/gutjnl-2022-327121","volume":"72","author":"Y Tong","year":"2023","unstructured":"Tong Y, Cheng PSW, Or CS, Yue SSK, Siu HC, Ho SL, et al. Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models. Gut. 2023;72:242\u201355.","journal-title":"Gut"},{"key":"2594_CR194","doi-asserted-by":"crossref","unstructured":"Kopper, O., de Witte, C.J., L Hmussaar, K., Valle-Inclan, J.E., Hami, N., Kester, L., Balgobind, A.V., Korving, J., Proost, N., and Begthel, H., et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 2019;25:838\u2013849.","DOI":"10.1038\/s41591-019-0422-6"},{"key":"2594_CR195","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2413954121","volume":"121","author":"R Ravindranathan","year":"2024","unstructured":"Ravindranathan R, Somuncu O, Da CA, Mukkavalli S, Lamarre BP, Nguyen H, et al. PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer. Proc Natl Acad Sci U S A. 2024;121:e2413954121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2594_CR196","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al. B7\u2013h3 as a therapeutic target in advanced prostate cancer. Eur Urol. 2023;83:224\u201338.","journal-title":"Eur Urol"},{"key":"2594_CR197","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","volume":"3","author":"KP Guillen","year":"2022","unstructured":"Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3:232\u201350.","journal-title":"Nat Cancer"},{"key":"2594_CR198","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41568-024-00694-7","volume":"24","author":"R Perez-Lopez","year":"2024","unstructured":"Perez-Lopez R, Ghaffari LN, Mahmood F, Kather JN. A guide to artificial intelligence for cancer researchers. Nat Rev Cancer. 2024;24:427\u201341.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR199","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/2159-8290.CD-22-1020","volume":"13","author":"PS Mundi","year":"2023","unstructured":"Mundi PS, Dela CF, Grunn A, Diolaiti D, Mauguen A, Rainey AR, et al. A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment-resistant malignancies. Cancer Discov. 2023;13:1386\u2013407.","journal-title":"Cancer Discov"},{"key":"2594_CR200","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1158\/0008-5472.CAN-23-1349","volume":"84","author":"BS White","year":"2024","unstructured":"White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, et al. A pan-cancer patient-derived xenograft histology image repository with genomic and pathologic annotations enables deep learning analysis. Cancer Res. 2024;84:2060\u201372.","journal-title":"Cancer Res"},{"key":"2594_CR201","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ccell.2021.04.002","volume":"39","author":"BH Kann","year":"2021","unstructured":"Kann BH, Hosny A, Aerts H. Artificial intelligence for clinical oncology. Cancer Cell. 2021;39:916\u201327.","journal-title":"Cancer Cell"},{"key":"2594_CR202","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s43018-020-0034-6","volume":"1","author":"O Troyanskaya","year":"2020","unstructured":"Troyanskaya O, Trajanoski Z, Carpenter A, Thrun S, Razavian N, Oliver N. Artificial intelligence and cancer. Nat Cancer. 2020;1:149\u201352.","journal-title":"Nat Cancer"},{"key":"2594_CR203","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-023-05881-4","volume":"616","author":"M Moor","year":"2023","unstructured":"Moor M, Banerjee O, Abad Z, Krumholz HM, Leskovec J, Topol EJ, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616:259\u201365.","journal-title":"Nature"},{"key":"2594_CR204","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/s41580-024-00775-3","volume":"25","author":"Z Wu","year":"2024","unstructured":"Wu Z, Qu J, Liu GH. Roles of chromatin and genome instability in cellular senescence and their relevance to ageing and related diseases. Nat Rev Mol Cell Biol. 2024;25:979\u20131000.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2594_CR205","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"M Fane","year":"2020","unstructured":"Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20:89\u2013106.","journal-title":"Nat Rev Cancer"},{"key":"2594_CR206","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.eng.2021.06.017","volume":"15","author":"Y He","year":"2022","unstructured":"He Y, Guo H, Diao L, Chen Y, Zhu J, Fernando HC, et al. Prediction of driver gene matching in lung cancer NOG\/PDX models based on artificial intelligence. Engineering. 2022;15:102\u201314.","journal-title":"Engineering"},{"key":"2594_CR207","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01929-7","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi Y, Ma J, Li S, Liu C, Liu Y, Chen J, et al. Sex difference in human diseases: mechanistic insights and clinical implications. Signal Transduct Target Ther. 2024;9:238.","journal-title":"Signal Transduct Target Ther"},{"key":"2594_CR208","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41586-023-06254-7","volume":"619","author":"J Li","year":"2023","unstructured":"Li J, Lan Z, Liao W, Horner JW, Xu X, Liu J, et al. Histone demethylase KDM5d upregulation drives sex differences in colon cancer. Nature. 2023;619:632\u20139.","journal-title":"Nature"},{"key":"2594_CR209","doi-asserted-by":"crossref","unstructured":"Youness A, Miquel CH, Guery JC. Escape from x chromosome inactivation and the female predominance in autoimmune diseases. Int J Mol Sci. 2021;22(3):1114.","DOI":"10.3390\/ijms22031114"},{"key":"2594_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49386-8","volume":"15","author":"S Baek","year":"2024","unstructured":"Baek S, Ha HS, Park JS, Cho MJ, Kim HS, Yu SE, et al. Chip collection of hepatocellular carcinoma based on o(2) heterogeneity from patient tissue. Nat Commun. 2024;15:5117.","journal-title":"Nat Commun"},{"key":"2594_CR211","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-023-01803-0","volume":"22","author":"E Bahrami","year":"2023","unstructured":"Bahrami E, Schmid JP, Jurinovic V, Becker M, Wirth AK, Ludwig R, et al. Combined proteomics and CRISPR-cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo. Mol Cancer. 2023;22:107.","journal-title":"Mol Cancer"},{"key":"2594_CR212","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-20-1851","volume":"12","author":"S Lin","year":"2022","unstructured":"Lin S, Larrue C, Scheidegger NK, Seong B, Dharia NV, Kuljanin M, et al. An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2022;12:432\u201349.","journal-title":"Cancer Discov"},{"key":"2594_CR213","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s43018-020-0040-8","volume":"1","author":"CH Hulton","year":"2020","unstructured":"Hulton CH, Costa EA, Shah NS, Quintanal-Villalonga A, Heller G, de Stanchina E, et al. Direct genome editing of patient-derived xenografts using CRISPR-cas9 enables rapid in vivo functional genomics. Nat Cancer. 2020;1:359\u201369.","journal-title":"Nat Cancer"},{"key":"2594_CR214","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41590-020-00857-2","volume":"22","author":"AL Graham","year":"2021","unstructured":"Graham AL. Naturalizing mouse models for immunology. Nat Immunol. 2021;22:111\u20137.","journal-title":"Nat Immunol"},{"key":"2594_CR215","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s43018-025-00917-2","volume":"6","author":"TG Chang","year":"2025","unstructured":"Chang TG, Park S, Sch Ffer AA, Jiang P, Ruppin E. Hallmarks of artificial intelligence contributions to precision oncology. Nat Cancer. 2025;6:417\u201331.","journal-title":"Nat Cancer"},{"key":"2594_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00299-z","volume":"6","author":"NA Fraunhoffer","year":"2022","unstructured":"Fraunhoffer NA, Abuelafia AAM, Bigonnet M, Gayet O, Roques J, Nicolle R, et al. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. NPJ Precis Oncol. 2022;6:57.","journal-title":"NPJ Precis Oncol"},{"key":"2594_CR217","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-024-00789-y","volume":"5","author":"X Shi","year":"2024","unstructured":"Shi X, Gekas C, Verduzco D, Petiwala S, Jeffries C, Lu C, et al. Building a translational cancer dependency map for the cancer genome atlas. Nat Cancer. 2024;5:1176\u201394.","journal-title":"Nat Cancer"},{"key":"2594_CR218","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12859-020-03633-z","volume":"21","author":"Y Kim","year":"2020","unstructured":"Kim Y, Kim D, Cao B, Carvajal R, Kim M. Pdxgem: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. BMC Bioinformatics. 2020;21:288.","journal-title":"BMC Bioinformatics"},{"key":"2594_CR219","doi-asserted-by":"crossref","unstructured":"Petrosyan, V., Dobrolecki, L.E., Thistlethwaite, L., Lewis, A.N., Sallas, C., Srinivasan, R.R., Lei, J.T., Kovacevic, V., Obradovic, P., and Ellis, M.J., et al. Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD\/WGCNA approach. iScience. 2022;26:105799.","DOI":"10.1016\/j.isci.2022.105799"},{"key":"2594_CR220","doi-asserted-by":"crossref","unstructured":"Ortmann J, Ramp\u00e1 Ek, L, Tai E, Mer AS, Shi R, Stewart EL, Mascaux C, Fares A, Pham NA, and Beri, G., et al. Assessing therapy response in patient-derived xenografts. Sci. Transl. Med. 2021;13:eabf4969.","DOI":"10.1126\/scitranslmed.abf4969"},{"key":"2594_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07371-9","volume":"23","author":"J Yang","year":"2025","unstructured":"Yang J, Wu T, Xue F, Gong J, Niu X. TRANSPIRE-DRP: a deep learning framework for translating patient-derived xenograft drug response to clinical patients via domain adaptation. J Transl Med. 2025;23:1340.","journal-title":"J Transl Med"},{"key":"2594_CR222","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02337-2","volume":"23","author":"J Ling","year":"2025","unstructured":"Ling J, Zhang J, Wang B, Fengsong J, Li T, Chen J. Artificial intelligence-driven discovery of YH395a: a novel TGF\u03b2R1 inhibitor with potent anti-tumor activity against triple-negative breast cancer. Cell Commun Signal. 2025;23:326.","journal-title":"Cell Commun Signal"},{"key":"2594_CR223","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2594_CR224","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535\u201354.","journal-title":"Lancet"},{"key":"2594_CR225","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s43018-020-0040-8","volume":"1","author":"CH Hulton","year":"2020","unstructured":"Hulton CH, Costa EA, Shah NS, Quintanal-Villalonga A, Heller G, de Stanchina E, et al. Direct genome editing of patient-derived xenografts using CRISPR-cas9 enables rapid in vivo functional genomics. Nat Cancer. 2020;1:359\u201369.","journal-title":"Nat Cancer"},{"key":"2594_CR226","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-020-03633-z","volume":"21","author":"Y Kim","year":"2020","unstructured":"Kim Y, Kim D, Cao B, Carvajal R, Kim M. Pdxgem: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. BMC Bioinformatics. 2020;21:288.","journal-title":"BMC Bioinformatics"},{"key":"2594_CR227","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2159-8290.CD-23-0656","volume":"14","author":"CS Pal","year":"2024","unstructured":"Pal CS, Girard L, Lim J, Wise JF, Freitas B, Yang D, et al. Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA amplification of MYC paralogs. Cancer Discov. 2024;14:804\u201327.","journal-title":"Cancer Discov"},{"key":"2594_CR228","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-23-0471","volume":"29","author":"S Chakraborty","year":"2023","unstructured":"Chakraborty S, Coleman C, Manoj P, Demircioglu D, Shah N, de Stanchina E, et al. De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways. Clin Cancer Res. 2023;29:3526\u201340.","journal-title":"Clin Cancer Res"},{"key":"2594_CR229","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1479246","volume":"2022","author":"C Wu","year":"2022","unstructured":"Wu C, Wang X, Shang H, Wei H. Construction of a humanized PBMC-PDX model to study the efficacy of a bacterial marker in lung cancer immunotherapy. Dis Markers. 2022;2022:1479246.","journal-title":"Dis Markers"},{"key":"2594_CR230","doi-asserted-by":"crossref","unstructured":"Oswald E, Bug D, Grote A, Lashuk K, Bouteldja N, Lenhard D, L\u00f6hr A, Behnke A, Knauff V, Edinger A, et al. Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up. J Immunother Cancer. 2022;10(4):e004412.","DOI":"10.1136\/jitc-2021-004412"},{"key":"2594_CR231","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s12885-018-4459-6","volume":"18","author":"S He","year":"2018","unstructured":"He S, Hu B, Li C, Lin P, Tang WG, Sun YF, et al. PDXliver: a database of liver cancer patient derived xenograft mouse models. BMC Cancer. 2018;18:550.","journal-title":"BMC Cancer"},{"key":"2594_CR232","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ijc.32564","volume":"146","author":"B Hu","year":"2020","unstructured":"Hu B, Li H, Guo W, Sun YF, Zhang X, Tang WG, et al. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2020;146:1606\u201317.","journal-title":"Int J Cancer"},{"key":"2594_CR233","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02407-8","volume":"18","author":"M Jian","year":"2020","unstructured":"Jian M, Ren L, He G, Lin Q, Tang W, Chen Y, et al. A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases. J Transl Med. 2020;18:234.","journal-title":"J Transl Med"},{"key":"2594_CR234","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-22-2630","volume":"29","author":"K Kinneer","year":"2023","unstructured":"Kinneer K, Wortmann P, Cooper ZA, Dickinson NJ, Masterson L, Cailleau T, et al. Design and preclinical evaluation of a novel b7-h4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305. Clin Cancer Res. 2023;29:1086\u2013101.","journal-title":"Clin Cancer Res"},{"key":"2594_CR235","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/0008-5472.CAN-15-2556","volume":"77","author":"G Chen","year":"2017","unstructured":"Chen G, Nakamura I, Dhanasekaran R, Iguchi E, Tolosa EJ, Romecin PA, et al. Transcriptional induction of periostin by a sulfatase 2-TGFbeta1-SMAD signaling axis mediates tumor angiogenesis in hepatocellular carcinoma. Cancer Res. 2017;77:632\u201345.","journal-title":"Cancer Res"},{"key":"2594_CR236","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13046-021-02011-8","volume":"40","author":"G Chen","year":"2021","unstructured":"Chen G, Wang Y, Zhao X, Xie XZ, Zhao JG, Deng T, et al. A positive feedback loop between periostin and TGFbeta1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2alpha activation. J Exp Clin Cancer Res. 2021;40:218.","journal-title":"J Exp Clin Cancer Res"},{"key":"2594_CR237","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301928","volume":"10","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang Y, Lu Z, Wan J, Jiang L, Song D, et al. PGAM1 inhibition promotes HCC ferroptosis and synergizes with anti-PD-1 immunotherapy. Adv Sci. 2023;10:e2301928.","journal-title":"Adv Sci"},{"key":"2594_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113783","volume":"383","author":"X Yin","year":"2025","unstructured":"Yin X, Zhao X, Shen Y, Xie W, He C, Guo J, et al. Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma. J Control Release. 2025;383:113783.","journal-title":"J Control Release"},{"key":"2594_CR239","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2594_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51909-2","volume":"15","author":"SM Leto","year":"2024","unstructured":"Leto SM, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, et al. XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients. Nat Commun. 2024;15:7495.","journal-title":"Nat Commun"},{"key":"2594_CR241","doi-asserted-by":"crossref","unstructured":"Ortmann, J., Rampasek, L., Tai, E., Mer, A.S., Shi, R., Stewart, E.L., Mascaux, C., Fares, A., Pham, N.A., and Beri, G., et al. Assessing therapy response in patient-derived xenografts. Sci. Transl. Med. 2021;13:eabf4969.","DOI":"10.1126\/scitranslmed.abf4969"},{"key":"2594_CR242","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.994333","volume":"12","author":"MP Kanikarla","year":"2022","unstructured":"Kanikarla MP, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, et al. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol. 2022;12:994333.","journal-title":"Front Oncol"},{"key":"2594_CR243","first-page":"73","volume":"52","author":"Z Wu","year":"2025","unstructured":"Wu Z, Lin X, Ying Y, Fan G, Shi J, Zheng X, et al. A dual-targeting strategy to inhibit colorectal cancer liver metastasis via tumor cell ferroptosis and cancer-associated fibroblast reprogramming. Bioact Mater. 2025;52:73\u201391.","journal-title":"Bioact Mater"},{"key":"2594_CR244","doi-asserted-by":"crossref","unstructured":"Kopetz S, Boni V, Kato K, Raghav K, Vieito M, Pallis A, Habermehl C, Siddiqui A, Courlet P, Sloot W, et al. Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med. 2025;31(10):3504\u201313.","DOI":"10.1038\/s41591-025-03843-z"},{"key":"2594_CR245","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669\u201385.","journal-title":"JAMA"},{"key":"2594_CR246","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0518-z","volume":"7","author":"A Capasso","year":"2019","unstructured":"Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019;7:37.","journal-title":"J Immunother Cancer"},{"key":"2594_CR247","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","volume":"15","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8\u201318.","journal-title":"Pancreatology"},{"key":"2594_CR248","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW, et al. Pancreatic cancer. Lancet. 2025;405:1182\u2013202.","journal-title":"Lancet"},{"key":"2594_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90049-1","volume":"11","author":"NA Pham","year":"2021","unstructured":"Pham NA, Radulovich N, Ibrahimov E, Martins-Filho SN, Li Q, Pintilie M, et al. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. Sci Rep. 2021;11:10619.","journal-title":"Sci Rep"},{"key":"2594_CR250","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.addr.2021.02.010","volume":"171","author":"T Golan","year":"2021","unstructured":"Golan T, Atias D, Stossel C, Raitses-Gurevich M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv Drug Deliv Rev. 2021;171:257\u201365.","journal-title":"Adv Drug Deliv Rev"},{"key":"2594_CR251","doi-asserted-by":"crossref","unstructured":"Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2018:PO.17.00286.","DOI":"10.1200\/PO.17.00286"},{"key":"2594_CR252","unstructured":"Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32(2):185-203.e13."},{"key":"2594_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101881","volume":"6","author":"GP Nagaraju","year":"2025","unstructured":"Nagaraju GP, Saddala MS, Foote JB, Khaliq AM, Masood A, Golivi Y, et al. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell Rep Med. 2025;6:101881.","journal-title":"Cell Rep Med"},{"key":"2594_CR254","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/j.gastro.2024.02.046","volume":"167","author":"Y Xie","year":"2024","unstructured":"Xie Y, Zhou T, Li X, Zhao K, Bai W, Hou X, et al. Targeting ESE3\/EHF with nifurtimox inhibits CXCR2(+) neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy. Gastroenterology. 2024;167:281\u201397.","journal-title":"Gastroenterology"},{"key":"2594_CR255","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00299-z","volume":"6","author":"NA Fraunhoffer","year":"2022","unstructured":"Fraunhoffer NA, Abuelafia AM, Bigonnet M, Gayet O, Roques J, Nicolle R, et al. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. NPJ Precis Oncol. 2022;6:57.","journal-title":"NPJ Precis Oncol"},{"key":"2594_CR256","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00682-z","volume":"14","author":"C Bernardo","year":"2025","unstructured":"Bernardo C, Chattopadhyay S, Andersson N, Eriksson P, Medle B, Tran L, et al. Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases. Exp Hematol Oncol. 2025;14:91.","journal-title":"Exp Hematol Oncol"},{"key":"2594_CR257","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/cac2.12470","volume":"43","author":"Y Li","year":"2023","unstructured":"Li Y, Zheng H, Luo Y, Lin Y, An M, Kong Y, et al. An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis. Cancer Commun. 2023;43:1289\u2013311.","journal-title":"Cancer Commun"},{"key":"2594_CR258","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1158\/0008-5472.CAN-21-4349","volume":"82","author":"M An","year":"2022","unstructured":"An M, Zheng H, Huang J, Lin Y, Luo Y, Kong Y, et al. Aberrant nuclear export of circNCOR1 underlies SMAD7-mediated lymph node metastasis of bladder cancer. Cancer Res. 2022;82:2239\u201353.","journal-title":"Cancer Res"},{"key":"2594_CR259","doi-asserted-by":"crossref","unstructured":"Li W, Chen C, Zheng H, Lin Y, An M, Liu D, Zhang Y, Gao M, Lan T, He W. UBE2c-induced crosstalk between mono- and polyubiquitination of SNAT2 promotes lymphatic metastasis in bladder cancer. J Clin Invest. 2024;134(13):e179122.","DOI":"10.1172\/JCI179122"},{"key":"2594_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103407","volume":"77","author":"J Zhang","year":"2024","unstructured":"Zhang J, Xu H, He Y, Zheng X, Lin T, Yang L, et al. Inhibition of KDM4a restricts SQLE transcription and induces oxidative stress imbalance to suppress bladder cancer. Redox Biol. 2024;77:103407.","journal-title":"Redox Biol"},{"key":"2594_CR261","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.640755","volume":"9","author":"H Lu","year":"2021","unstructured":"Lu H, Davis AJ. Human RecQ helicases in DNA double-strand break repair. Front Cell Dev Biol. 2021;9:640755.","journal-title":"Front Cell Dev Biol"},{"key":"2594_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02302-y","volume":"10","author":"X Li","year":"2025","unstructured":"Li X, Zhang C, Mei Y, Zhong W, Fan W, Liu L, et al. Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair. Signal Transduct Target Ther. 2025;10:214.","journal-title":"Signal Transduct Target Ther"},{"key":"2594_CR263","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-l1 via NEDD4 to control t-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114\u201329.","journal-title":"Cancer Res"},{"key":"2594_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101584","volume":"31","author":"Y Shi","year":"2025","unstructured":"Shi Y, Fan G, Yang E, Zhang Y, Ding H, Tian J, et al. Enhanced efficacy of immune checkpoint inhibitors by folate-targeted multifunctional drug through synergistic therapy inducing ferroptosis and immunogenic cell death in bladder cancer. Mater Today Bio. 2025;31:101584.","journal-title":"Mater Today Bio"},{"key":"2594_CR265","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369.","journal-title":"Lancet"},{"key":"2594_CR266","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1038\/s41598-025-06090-x","volume":"15","author":"N Fulcher","year":"2025","unstructured":"Fulcher N, Nguyen H, Deweyert A, Uzelac M, Mozaffari M, Zhang Q, et al. The SRG rat as a novel host for an orthotopic patient-derived xenograft model of breast cancer brain metastasis. Sci Rep. 2025;15:20932.","journal-title":"Sci Rep"},{"key":"2594_CR267","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.7150\/ijbs.112645","volume":"21","author":"A Lopez-Tejada","year":"2025","unstructured":"Lopez-Tejada A, Blaya-Canovas JL, Cara FE, Calahorra J, Ramirez-Tortosa C, Blancas I, et al. Signature-based repurposed drugs resemble the inhibition of TGFbeta-induced NDRG1 as potential therapeutics for triple-negative breast cancer. Int J Biol Sci. 2025;21:3949\u201367.","journal-title":"Int J Biol Sci"},{"key":"2594_CR268","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02337-2","volume":"23","author":"J Ling","year":"2025","unstructured":"Ling J, Zhang J, Wang B, Fengsong J, Li T, Chen J. Artificial intelligence-driven discovery of YH395a: a novel TGFbetaR1 inhibitor with potent anti-tumor activity against triple-negative breast cancer. Cell Commun Signal. 2025;23:326.","journal-title":"Cell Commun Signal"},{"key":"2594_CR269","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18374","volume":"28","author":"Y Cui","year":"2024","unstructured":"Cui Y, Ran R, Da Y, Zhang H, Jiang M, Qi X, et al. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment. J Cell Mol Med. 2024;28:e18374.","journal-title":"J Cell Mol Med"},{"key":"2594_CR270","first-page":"276","volume":"29","author":"CU Joisa","year":"2024","unstructured":"Joisa CU, Chen KA, Beville S, Stuhlmiller T, Berginski ME, Okumu D, et al. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies. Pac Symp Biocomput. 2024;29:276\u201390.","journal-title":"Pac Symp Biocomput"},{"key":"2594_CR271","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/2159-8290.CD-23-0838","volume":"14","author":"TP Diperi","year":"2024","unstructured":"Diperi TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, et al. Co-clinical trial of novel bispecific anti-HER2 antibody zanidatamab in patient-derived xenografts. Cancer Discov. 2024;14:828\u201345.","journal-title":"Cancer Discov"},{"key":"2594_CR272","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-21-1299","volume":"28","author":"H Kurani","year":"2022","unstructured":"Kurani H, Razavipour SF, Harikumar KB, Dunworth M, Ewald AJ, Nasir A, et al. DOT1l is a novel cancer stem cell target for triple-negative breast cancer. Clin Cancer Res. 2022;28:1948\u201365.","journal-title":"Clin Cancer Res"},{"key":"2594_CR273","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.21873\/anticanres.17318","volume":"44","author":"J Chantaraamporn","year":"2024","unstructured":"Chantaraamporn J, Pothipan P, Sakulterdkiat T, Khiankaew B, Lumkul L, Mutapat P, et al. CD47 and calreticulin expression in breast cancer subtypes and anti-CD47 inhibitory effects in macrophage-mediated phagocytosis. Anticancer Res. 2024;44:4929\u201340.","journal-title":"Anticancer Res"},{"key":"2594_CR274","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101068","volume":"74","author":"B Zhang","year":"2024","unstructured":"Zhang B, Shi J, Shi X, Xu X, Gao L, Li S, et al. Development and evaluation of a human CD47\/HER2 bispecific antibody for trastuzumab-resistant breast cancer immunotherapy. Drug Resist Update. 2024;74:101068.","journal-title":"Drug Resist Update"},{"key":"2594_CR275","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4048\/jbc.2023.0177","volume":"27","author":"Y Her","year":"2024","unstructured":"Her Y, Yun J, Son HY, Heo W, Kim JI, Moon HG. Potential perturbations of critical cancer-regulatory genes in triple-negative breast cancer cells within the humanized microenvironment of patient-derived xenograft models. J Breast Cancer. 2024;27:37\u201353.","journal-title":"J Breast Cancer"},{"key":"2594_CR276","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2017.07.002","volume":"32","author":"H Jia","year":"2017","unstructured":"Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Update. 2017;32:1\u201315.","journal-title":"Drug Resist Update"},{"key":"2594_CR277","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18498","volume":"9","author":"Y Li","year":"2023","unstructured":"Li Y, Li Y, Yang Y, Deng Y, Ni X, Zhao B, et al. Synergistic efficacy of PI3kdelta inhibitor with anti-PD-1 mabs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer. Heliyon. 2023;9:e18498.","journal-title":"Heliyon"},{"key":"2594_CR278","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402:485\u2013502.","journal-title":"Lancet"},{"key":"2594_CR279","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100759","volume":"4","author":"S Domanskyi","year":"2024","unstructured":"Domanskyi S, Srivastava A, Kaster J, Li H, Herlyn M, Rubinstein JC, et al. Nextflow pipeline for Visium and H&E data from patient-derived xenograft samples. Cell Rep Methods. 2024;4:100759.","journal-title":"Cell Rep Methods"},{"key":"2594_CR280","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jconrel.2020.05.025","volume":"324","author":"L Shi","year":"2020","unstructured":"Shi L, Wang Y, Wang Q, Jiang Z, Ren L, Yan Y, et al. Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts. J Control Release. 2020;324:289\u2013302.","journal-title":"J Control Release"},{"key":"2594_CR281","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv6990","volume":"11","author":"Y Gu","year":"2025","unstructured":"Gu Y, Li A, Zeng Y, He M, Qi F, Liu R, et al. Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3a4-siRNA against pulmonary metastatic melanoma. Sci Adv. 2025;11:eadv6990.","journal-title":"Sci Adv"},{"key":"2594_CR282","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101995","volume":"6","author":"W Wang","year":"2025","unstructured":"Wang W, Li X, Hu R, Dong L, Pei S, Jin L, et al. BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma. Cell Rep Med. 2025;6:101995.","journal-title":"Cell Rep Med"},{"key":"2594_CR283","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.annonc.2019.11.002","volume":"31","author":"L Ny","year":"2020","unstructured":"Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen H, Carstam L, et al. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Ann Oncol. 2020;31:266\u201373.","journal-title":"Ann Oncol"},{"key":"2594_CR284","doi-asserted-by":"publisher","first-page":"12695","DOI":"10.1021\/acsnano.2c04420","volume":"16","author":"SZ Al","year":"2022","unstructured":"Al SZ, Poschel DB, Redd PS, Klement JD, Merting AD, Yang D, et al. Lipid nanoparticle delivery of fas plasmid restores fas expression to suppress melanoma growth in vivo. ACS Nano. 2022;16:12695\u2013710.","journal-title":"ACS Nano"},{"key":"2594_CR285","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ajh.27708","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Jabbour E. Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2025;100:1205\u201331.","journal-title":"Am J Hematol"},{"key":"2594_CR286","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"2594_CR287","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","volume":"33","author":"T Maes","year":"2018","unstructured":"Maes T, Mascaro C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, et al. ORY-1001, a potent and selective covalent KDM1a inhibitor, for the treatment of acute leukemia. Cancer Cell. 2018;33:495.","journal-title":"Cancer Cell"},{"key":"2594_CR288","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2217\/fon-2021-1288","volume":"18","author":"MJ Burke","year":"2022","unstructured":"Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia\u202f: immunology and clinical consequences. Future Oncol. 2022;18:1285\u201399.","journal-title":"Future Oncol"},{"key":"2594_CR289","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1182\/blood.2021011787","volume":"138","author":"M Butler","year":"2021","unstructured":"Butler M, van Ingen Schenau DS, Yu J, Jenni S, Dobay MP, Hagelaar R, et al. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood. 2021;138:2383\u201395.","journal-title":"Blood"},{"key":"2594_CR290","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41571-023-00766-x","volume":"20","author":"CC Wong","year":"2023","unstructured":"Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol. 2023;20:429\u201352.","journal-title":"Nat Rev Clin Oncol"},{"key":"2594_CR291","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2217\/pgs.15.102","volume":"16","author":"D Sia","year":"2015","unstructured":"Sia D, Moeini A, Labgaa I, Villanueva A. The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics. 2015;16:1671\u201383.","journal-title":"Pharmacogenomics"},{"key":"2594_CR292","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s43018-023-00717-6","volume":"5","author":"M Nikolski","year":"2024","unstructured":"Nikolski M, Hovig E, Al-Shahrour F, Blomberg N, Scollen S, Valencia A, et al. Roadmap for a European cancer data management and precision medicine infrastructure. Nat Cancer. 2024;5:367\u201372.","journal-title":"Nat Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02594-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02594-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02594-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:02:52Z","timestamp":1774440172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02594-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":292,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2594"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02594-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}